A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.
Incyte Corporation
DEKA Biosciences
The Netherlands Cancer Institute
Second Affiliated Hospital of Guangzhou Medical University
Celldex Therapeutics
Eye & ENT Hospital of Fudan University
Myeloid Therapeutics
Massachusetts General Hospital
Fred Hutchinson Cancer Center
Peking University Cancer Hospital & Institute
GlaxoSmithKline
University of Utah
AVAX Technologies
Bristol-Myers Squibb
Pfizer
FeRx